David A. Siegel Crispr Therapeutics Ag Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Two Sigma Advisers, LP holds 56,400 shares of CRSP stock, worth $2.35 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
56,400Holding current value
$2.35 Million% of portfolio
0.01%Shares
19 transactions
Others Institutions Holding CRSP
# of Institutions
485Shares Held
57.5MCall Options Held
1.09MPut Options Held
1.9M-
Capital International Investors Los Angeles, CA7.93MShares$330 Million0.07% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl7.5MShares$312 Million3.35% of portfolio
-
State Street Corp Boston, MA2.99MShares$124 Million0.01% of portfolio
-
Nikko Asset Management Americas, Inc.2.97MShares$123 Million1.61% of portfolio
-
Black Rock Inc. New York, NY2.78MShares$116 Million0.0% of portfolio
About CRISPR Therapeutics AG
- Ticker CRSP
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 78,009,296
- Market Cap $3.24B
- Description
- CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....